SEARCH

SEARCH BY CITATION

References

  • 1
    Lamers CB, Griffioen G, Van Hogezand RA, Veenendaal RA. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 1115.
  • 2
    Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973; 115: 11006.
  • 3
    Armenti VT, Moritz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Drug Saf 1998; 19: 21932.
  • 4
    Meuwissen SG, Ewe K, Gassull MA, et al. IOIBD questionnaire on the clinical use of azathioprine, mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000; 12: 138.
  • 5
    Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 917.
  • 6
    Rajapakse RO, Korelitz BI, Zlatanic J, Baiocco PJ, Gleim GW. Outcome of pregnancies when fathers are treated with mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000; 95: 6848.
    Direct Link:
  • 7
    Ben Neriah Z, Ackerman Z. WAGR syndrome in a baby — the result of 6-MP treatment in a father affected by Crohn's disease? Am J Gastroenterol 2001; 96: 251.
  • 8
    Kane SV. What's good for the goose should be good for the gander — 6-MP use in fathers with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 5812.
  • 9
    Korelitz BI, Rajapakse RO, Zlatanic J, Baiocco PJ, Gleim GW. 6MP for fathers with IBD at the time of conception: the value of a large clinical experience over unrelated controls. Am J Gastroenterol 2000; 95: 23867.
    Direct Link:
  • 10
    Katz JA, Pore G. Inflammatory bowel disease and pregnancy. Inflamm Bowel Dis 2001; 7: 14657.
  • 11
    Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf 1999; 21: 31123.
  • 12
    Joffe JM. Influence of drug exposure of the father on perinatal outcome. Clin Perinatol 1979; 6: 2136.
  • 13
    Joffe JM, Soyka LF. Paternal drug exposure: effects on reproduction and progeny. Semin Perinatol 1982; 6: 11624.
  • 14
    Mosesso P, Palitti F. The genetic toxicology of mercaptopurine. Mutat Res 1993; 296: 27994.
  • 15
    Oakberg EF, Crosthwait CD, Raymer GD. Spermatogenic stage sensitivity to mercaptopurine in the mouse. Mutat Res 1982; 94: 16578.
  • 16
    Russell LB, Hunsicker PR. Study of the base analog mercaptopurine in the mouse specific-locus test. Mutat Res 1987; 176: 4752.
  • 17
    Generoso WM, Preston RJ, Brewen JG. 6-Mercaptopurine, an inducer of cytogenetic and dominant-lethal effects in premeiotic and early meiotic germ cells of male mice. Mutat Res 1975; 28: 43747.
  • 18
    Friedman JM, Polifka JE. The Effects of Drugs on the Fetus and Nursing Infant. Baltimore: Johns Hopkins University Press, 1996.
  • 19
    Larsen H, Nielsen GL, Bendsen J, Flint C, Olsen J, Sorensen HT. Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries. Scand J Public Health 2003; 31: 126.
  • 20
    Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998; 45: 3203.
  • 21
    Mitchell AA. Special considerations in studies of drug-induced birth defects. In: StromBL, ed. Pharmacoepidemiology, 3rd edn. Chichester: John Wiley & Sons, 2002: 74963.
  • 22
    West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 110312.